01—Abstract
Summary
Summary of the 8-K filed April 21, 2026. Cited figures are marked; the original filing is the authoritative source.
UnitedHealth Group reported first quarter 2026 results that showed modest top-line growth and improved medical cost performance, while operating costs rose sharply.
Total revenues were $111.7 billiona, up 2% year over year, and earnings from operations were $9.0 billion, roughly flat versus $9.1 billion a year earlier. GAAP diluted EPS was $6.90 and adjusted EPS was $7.23, compared with $6.85 and $7.20 in the prior-year quarter. The medical care ratio improved 90 basis points to 83.9%, driven by cost management and favorable reserve development, but the operating cost ratio rose to 13.8% from 12.4% as the company invests in people, technology and AI.
Management raised its full-year 2026 outlook to GAAP diluted EPS of greater than $17.35b and adjusted EPS of greater than $18.25. The company is also executing a portfolio refocus on U.S. health care, having completed the sale of Optum UK, with $400 million of proceeds committed to the United Health Foundation, and agreeing to acquire Alegeus Technologies, which is expected to close in the second half of 2026. It also plans to repurchase at least $2 billion of common stock by the end of Q2 2026 and expects its debt-to-capital ratio to reach about 40% in the second half of 2026, down from 42.9% at quarter end.
The quarter also showed some pressure points. UnitedHealthcare membership fell, with Medicare Advantage seniors down 965,000 and Community & State people served down 220,000, and Optum Rx adjusted scripts declined to 383 million from 408 million.
Optum Health revenue fell 3%c as value-based care membership shrank. Investors will likely focus on whether the operating cost investments produce efficiency gains and whether membership attrition stabilizes.
02—Key points
Key Highlights
- Total revenues of $111.7 billion, up 2% year over year, with UnitedHealthcare revenue of $86.3 billion and Optum revenue of $63.7 billion.
- Medical care ratio improved 90 basis points to 83.9% from 84.8%, driven by strong medical cost management and favorable reserve development, partly offset by elevated utilization and unit cost trends.
- Operating cost ratio rose to 13.8% from 12.4% as the company invested in people, processes, technology and artificial intelligence.
- GAAP diluted EPS of $6.90 and adjusted EPS of $7.23, versus $6.85 and $7.20 a year earlier; full-year 2026 outlook raised to greater than $17.35 GAAP and greater than $18.25 adjusted.
- Capital actions: at least $2.0 billion of share repurchases expected by end of Q2 2026, debt-to-capital ratio of 42.9% (target ~40% in H2 2026), and cash flow from operations of $8.9 billion.
- Portfolio changes: completed sale of Optum UK with $400 million of proceeds committed to the United Health Foundation, and agreed to acquire Alegeus Technologies (expected close in H2 2026, earnings neutral for 2026).
- Membership pressure persisted: Medicare Advantage seniors served fell by 965,000, Community & State people served fell by 220,000, and Optum Rx adjusted scripts declined to 383 million from 408 million.
03—Questions
Frequently Asked Questions
Why did UnitedHealth raise its 2026 earnings outlook despite higher operating costs?
The raised outlook reflects a better medical cost position. The medical care ratio improved to 83.9% from 84.8% on cost management and favorable reserve development, which more than offset the rise in the operating cost ratio to 13.8% from 12.4%. Management expects full-year GAAP EPS of greater than $17.35 and adjusted EPS of greater than $18.25.
What is the difference between GAAP and adjusted EPS in this quarter?
GAAP diluted EPS was $6.90 and adjusted EPS was $7.23. The adjustments add back intangible amortization ($0.37 per share) and remove net portfolio divestiture and South American impacts (a $0.17 per share benefit, which is subtracted), along with restructuring and other items (a $0.22 per share net charge, mainly the $400 million United Health Foundation contribution, partly offset by reserve reductions and equity gains), net of tax effects of $0.09 per share.
How is UnitedHealth's capital position changing?
Debt-to-capital fell to 42.9% at March 31, 2026, from 43.9% at year-end 2025 and 44.6% a year earlier, and management targets about 40% in the second half of 2026. The company plans to repurchase at least $2.0 billion of stock by the end of Q2 2026, having made no repurchases in Q1 2026 compared with $3.0 billion a year earlier. Quarterly dividends paid were $2.0 billion.
Why are membership and revenue trends mixed across the business?
UnitedHealthcare revenue grew 2% to $86.3 billion, supported by repricing across lines of business, but enrollment is shrinking in key segments. Medicare Advantage seniors fell by 965,000 and Community & State people served fell by 220,000, the latter largely due to early state eligibility changes. Optum Rx revenue rose 2%, but earnings fell as UHC membership attrition reduced volume. Optum Health revenue fell 3% as value-based care membership declined.
What are the main strategic moves investors should track?
The company is refocusing on U.S. health care by exiting non-U.S. businesses, having sold Optum UK and still working through its remaining South American operations. It is also investing heavily in artificial intelligence and cybersecurity, and it agreed to acquire Alegeus Technologies, a consumer-directed benefits administration platform, subject to regulatory review. Leadership changes included refreshing nearly half of the top 100 leadership roles and adding board governance changes.
04—Continue